Sonoma Pharmaceuticals, Inc. (SNOA, Financial) experienced a notable increase in its stock price, rising by 7.34% to $3.07 per share. The trading volume reached 94,787 shares with a turnover rate of 7.08% and a price fluctuation of 8.37%.
According to the latest financial reports, Sonoma Pharmaceuticals posted a revenue of $3.39 million and a net loss of $1.14 million, resulting in an earnings per share (EPS) of -$1.34. The company recorded a gross profit of $1.31 million, with a price-to-earnings (P/E) ratio of -0.50. Notably, of the institutions providing ratings, 100% have recommended buying the stock.
In the pharmaceuticals sector, where Sonoma operates, the overall decline was 0.36%. Among related stocks, notable gainers included NeuroRegen Tech and Nature's Sunshine Products, while Sonoma Pharmaceuticals, Inc., Nature's Sunshine Products, and Biofrontera Inc. showed significant activity with turnover rates of 11.78%, 7.08%, and 4.83%, respectively. Stocks with high volatility included Sunshine Biopharma Inc., NeuroRegen Tech, and Nature's Sunshine Products, with amplitudes of 30.04%, 22.49%, and 20.04%, respectively.
Sonoma Pharmaceuticals Inc. is a U.S.-based specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated therapies for chronic skin conditions. The company's product range includes Celacyn, Ceramax Barrier Cream, Mondoxyne, alevyyn, SebuDerm, and Microcyn, targeting treatments for scars, itching, minor skin irritations, and rashes. Sonoma generates revenue from product sales across the U.S., Latin America, Europe, Asia, and other markets.
